3/11
03:12 am
vstm
https://seekingalpha.com/article/4766357-verastem-upcoming-pdufa-but-i-remain-cautious [Seeking Alpha]
Low
Report
https://seekingalpha.com/article/4766357-verastem-upcoming-pdufa-but-i-remain-cautious [Seeking Alpha]
2/20
04:27 pm
vstm
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer [Yahoo! Finance]
Low
Report
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer [Yahoo! Finance]
2/20
04:05 pm
vstm
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
Low
Report
Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
1/31
12:43 pm
vstm
Verastem, Inc. (NASDAQ: VSTM) had its price target raised by analysts at B. Riley from $7.00 to $9.00. They now have a "buy" rating on the stock.
Medium
Report
Verastem, Inc. (NASDAQ: VSTM) had its price target raised by analysts at B. Riley from $7.00 to $9.00. They now have a "buy" rating on the stock.
1/29
07:30 am
vstm
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
Medium
Report
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
1/24
11:30 am
vstm
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at Guggenheim.
Medium
Report
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at Guggenheim.
1/23
07:30 am
vstm
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
Low
Report
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
1/15
07:30 am
vstm
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
Medium
Report
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
1/14
07:30 am
vstm
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
Medium
Report
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
1/13
07:30 am
vstm
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
Medium
Report
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
1/8
07:30 am
vstm
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/7
10:24 am
vstm
Verastem, Inc. (NASDAQ: VSTM) had its price target raised by analysts at Royal Bank of Canada from $13.00 to $16.00. They now have an "outperform" rating on the stock.
Medium
Report
Verastem, Inc. (NASDAQ: VSTM) had its price target raised by analysts at Royal Bank of Canada from $13.00 to $16.00. They now have an "outperform" rating on the stock.
12/31
10:36 am
vstm
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application [Yahoo! Finance]
Medium
Report
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application [Yahoo! Finance]
12/31
09:10 am
vstm
Verastem, Inc. (NASDAQ: VSTM) had its price target raised by analysts at BTIG Research from $13.00 to $20.00. They now have a "buy" rating on the stock.
Medium
Report
Verastem, Inc. (NASDAQ: VSTM) had its price target raised by analysts at BTIG Research from $13.00 to $20.00. They now have a "buy" rating on the stock.
12/30
04:30 pm
vstm
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
High
Report
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
12/19
09:16 am
vstm
Verastem, Inc. (NASDAQ: VSTM) had its price target raised by analysts at Mizuho from $7.00 to $9.00. They now have an "outperform" rating on the stock.
Medium
Report
Verastem, Inc. (NASDAQ: VSTM) had its price target raised by analysts at Mizuho from $7.00 to $9.00. They now have an "outperform" rating on the stock.
12/19
08:10 am
vstm
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
12/18
07:36 am
vstm
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer [Yahoo! Finance]
Medium
Report
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer [Yahoo! Finance]
12/18
07:30 am
vstm
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Medium
Report
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer